<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01199562</url>
  </required_header>
  <id_info>
    <org_study_id>09038</org_study_id>
    <secondary_id>NCI-2010-01932</secondary_id>
    <nct_id>NCT01199562</nct_id>
  </id_info>
  <brief_title>Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant</brief_title>
  <official_title>Modified Pre-emptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV)
      infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection
      prophylaxis and management in treating cytomegalovirus infection in patients with
      hematologic malignancies previously treated with donor stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To evaluate the efficacy and safety of a individualized strategy for
      CMV preemptive management, one that monitors CMV viral load and clinical markers of
      immunosuppression to optimize use of ganciclovir in recipients of allogeneic HCT
      (Hematopoietic Cell Transplant) who experience CMV reactivation. SECONDARY OBJECTIVES: I. To
      investigate how donor Killer Immunoglobulin-like Receptor (KIR) genes of interest
      (activating KIR2DS2 and 2DS4, inhibitory KIR2DL1, 2DL2/2DL3, 3DL1, 3DL2), together with
      their recipient ligands where known, influence CMV reactivation-free survival after
      allogeneic HCT, independently of clinical risk factors such as onset of acute
      graft-versus-host disease. II. To investigate whether markers of Natural Killer (NK) cell
      function correlate with a) KIR/ligand compound genotype and baseline or concurrent clinical
      factors and b) with history of CMV reactivation and anti-CMV therapy at the time of NK cell
      collection. OUTLINE: Patients receive standard antiviral infection prophylaxis and
      management comprising ganciclovir (GCV), valganciclovir, or foscarnet sodium for 2 weeks or
      until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on
      subsequent CMV reactivations. After completion of study treatment, patients are followed up
      periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Supportive Care</study_design>
  <primary_outcome>
    <measure>Gancyclovir initiation</measure>
    <time_frame>Day 80 post stem cell transplant</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>NK (natural killer) immunity in CMV (cytomegalovirus) negative vs CMV positive</measure>
    <time_frame>Day 80 post stem cell transplant</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis of CMV pneumonia</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMV disease, morbidity, and mortality</measure>
    <time_frame>Through 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of an individualized strategy for CMV preemptive management on incidence of CMV disease, specifically CMV pneumonia</measure>
    <time_frame>By day 80 post transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV reaction-free survival</measure>
    <time_frame>Post-transplant days 21 - 80</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent cytotoxicity and ex vivo percent CD56+/CD107B+ cells</measure>
    <time_frame>Day 80 post stem cell transplant</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hematopoietic/Lymphoid Cancer</condition>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Atypical Chronic Myeloid Leukemia, BCR-ABL Negative</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Eosinophilic Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Neutrophilic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Contiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Contiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Contiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Contiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>Cytomegalovirus Infection</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Extramedullary Plasmacytoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Isolated Plasmacytoma of Bone</condition>
  <condition>Mast Cell Leukemia</condition>
  <condition>Meningeal Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Noncontiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Progressive Hairy Cell Leukemia, Initial Treatment</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Secondary Myelofibrosis</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage 0 Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Adult Burkitt Lymphoma</condition>
  <condition>Stage I Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage I Adult Hodgkin Lymphoma</condition>
  <condition>Stage I Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage I Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage I Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage I Grade 1 Follicular Lymphoma</condition>
  <condition>Stage I Grade 2 Follicular Lymphoma</condition>
  <condition>Stage I Grade 3 Follicular Lymphoma</condition>
  <condition>Stage I Mantle Cell Lymphoma</condition>
  <condition>Stage I Marginal Zone Lymphoma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage I Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage I Small Lymphocytic Lymphoma</condition>
  <condition>Stage II Adult Hodgkin Lymphoma</condition>
  <condition>Stage II Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage II Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage II Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage III Adult Burkitt Lymphoma</condition>
  <condition>Stage III Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage III Adult Hodgkin Lymphoma</condition>
  <condition>Stage III Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage III Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage III Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Stage III Mantle Cell Lymphoma</condition>
  <condition>Stage III Marginal Zone Lymphoma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>Stage III Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Hodgkin Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <condition>T-cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>infection prophylaxis and management</intervention_name>
    <description>Undergo infection prophylaxis and management</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>treatment of infectious disease</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <description>undergo infection prophylaxis and management</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>complications of therapy, management of</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganciclovir</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BW 759U</other_name>
    <other_name>BW-B759U</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valganciclovir</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Valcyte</other_name>
    <other_name>VGCV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>foscarnet sodium</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Foscavir</other_name>
    <other_name>trisodium phosphonoformate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiviral therapy</intervention_name>
    <description>undergo infection prophylaxis and management</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>therapy, antiviral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis: hematologic malignancies/disorders including aplastic anemia and
             myelodysplastic syndrome

          -  Procedure: first allogeneic, T cell-replete transplantation of stem-cells from
             peripheral blood or bone marrow of an human leukocyte antigen (HLA)matched, unrelated
             or nonsyngeneic sibling donor

          -  CMV seropositive donor and/or recipient

          -  Performance level: must have already been determined to be eligible for HCT at City
             of Hope (COH)

          -  Prior Therapy: No prior HCT

          -  Organ function requirements: does not apply because recipients will have met organ
             function requirements for HCT

          -  Informed Consent: All patients must be capable of signing a written informed consent
             and no consent can be provided by a legal guardian

        Exclusion Criteria:

          -  The recipient had prior polymerase chain reaction (PCR) positive CMV infection in
             blood or organ-specific disease in the past 12 months

          -  The source of hematopoietic stem cells is T-cell depleted

          -  Concomitant anti-graft-versus-host disease (GVD) treatment includes in vivo T cell
             depletion

          -  Recipient is human immunodeficiency virus (HIV)-1 positive
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryotaro Nakamura</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryotaro Nakamura</last_name>
      <phone>626-256-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ryotaro Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 6, 2011</lastchanged_date>
  <firstreceived_date>September 8, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Nakamura, Ryotaro</name_title>
    <organization>City of Hope Medical Center</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Neutrophilic, Chronic</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
</clinical_study>
